Switching from anti-CGRP-receptor mAb (erenumab) to an antiCGRP-molecule mAbs (fremanezumab) in chronic migraine: results of a real-world study

被引：0
|
作者：
Caponnetto, V. [1 ,2 ]
Hill, B. [2 ]
Murphy, M. [2 ]
Ighavini, O. [2 ]
Briscoe, J. [2 ]
Arruda, R. [3 ]
Andreou, A. P. [2 ,4 ,5 ]
Lambru, G. [2 ,4 ]
机构：
[1] Univ LAquila, Dept Appl Clin Sci & Biotechnol, Laquila, Italy
[2] Guys & St Thomas NHS Fdn Trust, Headache Ctr, London, England
[3] Univ Sao Paulo, MSc Dept Neurosci & Behav Sci, Ribeirao Preto, Brazil
[4] Kings Coll London, Inst Psychiat Psychol & Neurosci, London, England
[5] Kings Coll London, Inst Psychol Psychiat & Neurosci, Headache Res Wolfson CARD, London, England
来源：
JOURNAL OF HEADACHE AND PAIN | 2022年 / 23卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P257
引用
收藏
页数：2
相关论文
共 37 条
  • [1] Switching anti-CGRP monoclonal antibodies in chronic migraine: real-world observations of erenumab, fremanezumab and galcanezumab
    Talbot, Jamie
    Stuckey, Rebecca
    Wood, Natasha
    Gordon, Alexander
    Crossingham, Ginette
    Weatherby, Stuart
    [J]. EUROPEAN JOURNAL OF HOSPITAL PHARMACY, 2024,
  • [2] Real-world effectiveness of fremanezumab in patients with migraine switching from another mAb targeting the CGRP pathway: a subgroup analysis of the Finesse Study
    Andreas Straube
    Gregor Broessner
    Charly Gaul
    Xenia Hamann
    Joachim Hipp
    Torsten Kraya
    Lars Neeb
    [J]. The Journal of Headache and Pain, 24
  • [3] Real-world effectiveness of fremanezumab in patients with migraine switching from another mAb targeting the CGRP pathway: a subgroup analysis of the Finesse Study
    Straube, Andreas
    Broessner, Gregor
    Gaul, Charly
    Hamann, Xenia
    Hipp, Joachim
    Kraya, Torsten
    Neeb, Lars
    [J]. JOURNAL OF HEADACHE AND PAIN, 2023, 24 (01):
  • [4] Effect of switching to erenumab in non-responders to a CGRP ligand antibody treatment in migraine: A real-world cohort study
    Overeem, Lucas Hendrik
    Lange, Kristin Sophie
    Fitzek, Mira Pauline
    Siebert, Anke
    Steinicke, Maureen
    Triller, Paul
    Hong, Ja Bin
    Reuter, Uwe
    Raffaelli, Bianca
    [J]. FRONTIERS IN NEUROLOGY, 2023, 14
  • [5] Pooled Analysis of Real-World Evidence Supports Anti-CGRP mAbs and OnabotulinumtoxinA Combined Trial in Chronic Migraine
    Scuteri, Damiana
    Tonin, Paolo
    Nicotera, Pierluigi
    Vulnera, Marilu
    Altieri, Giuseppina Cristina
    Tarsitano, Assunta
    Bagetta, Giacinto
    Corasaniti, Maria Tiziana
    [J]. TOXINS, 2022, 14 (08)
  • [6] Real-world effectiveness of switching to fremanezumab from other CGRP pathway targeting mAbs: PEARL 3rd interim analysis
    Ashina, M.
    Mitsikostas, D.
    Amin, F.
    Kokturk, P.
    Schankin, C.
    Sahin, G.
    Pozo-Rosich, P.
    Dorman, P.
    Nezadal, T.
    Poole, A.
    Martins, I.
    Sumelahti, M.
    Campos, V. Ramirez
    Ning, X.
    Akcicek, H.
    Tassorelli, C.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 : 371 - 372
  • [7] Real-World Effectiveness of Fremanezumab in Patients with Migraine who Switched From Another mAb Targeting the CGRP Pathway (Subgroup Analysis From FINESSE)
    Straube, Andreas
    Broessner, Gregor
    Gaul, Charly
    Hamann, Xenia
    Hipp, Joachim
    Kraya, Torsten
    Schauerte, Isabel
    Neeb, Lars
    [J]. NEUROLOGY, 2023, 100 (17)
  • [8] Real-world effectiveness of fremanezumab in patients with migraine who switched from another mAb targeting the CGRP pathway (subgroup analysis from FINESSE)
    Straube, A.
    Broessner, G.
    Gaul, C.
    Hamann, X.
    Hipp, J.
    Kraya, T.
    Schauerte, I
    Neeb, L.
    [J]. HEADACHE, 2023, 63 : 158 - 159
  • [9] No wearing-off effect of erenumab or fremanezumab for chronic migraine prevention: a single-center, real-world, observational study
    Florescu, Anna Maria
    Lannov, Laerke Vig
    Younis, Samaira
    Cullum, Christopher Kjaer
    Chaudhry, Basit Ali
    Do, Thien Phu
    Amin, Faisal Mohammad
    [J]. CEPHALALGIA, 2024, 44 (01)
  • [10] Long-Term Effect of Switching From an Anti-CGRP Receptor to an Anti-CGRP Ligand Antibody in Treatment-Refractory Chronic Migraine: A Prospective Real-World Analysis
    Giorgio Lambru
    Valeria Caponnetto
    Bethany Hill
    Susanna Ratti
    Simona Sacco
    Madeleine Murphy
    Jessica Briscoe
    Anna P. Andreou
    [J]. Neurotherapeutics, 2023, 20 : 1284 - 1293
1234